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The semi-synthesis of 11 isatin derivatives was achieved through bimolecular nucleophilic 
substitution and click chemistry. Seven new compounds were obtained. All chemical structures 
were determined by infrared spectroscopy (IR), nuclear magnetic resonance spectrometry (NMR) 
and high-resolution mass spectrometry (HRMS) data. These derivatives were evaluated for their 
anti-GSK-3β activity and all isatin derivatives (N-alkyl and 1,2,3-triazolic) exhibited strong 
inhibitory activity, with 2b and 4h exhibiting remarkable potency. In addition, docking studies 
were performed with 2b and 2e models to unravel the molecular mechanism underlying the polar 
interactions on the GSK-3β ATP-binding site.
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Introduction
Isatin (1H-indole-2,3-dione), first synthesized by 
Erdmann1 and Laurent2 in 1840, results from the 
reaction of indigo with nitric and chromium acids. This 
molecule has been isolated from Bufo frogs, fungi and 
marine molluscs.3 In plants, the isatin alkaloid was 
found in Strobilanthes cusia (Nees), Isatis tinctoria L.,4 
Couroupita guianesis Aubl.5 and Calanthe discolor.6 These 
plants have an ethnic relevance in traditional Chinese 
therapeutics.3
The Sandmeyer method7 is a broadly used procedure 
to synthesize isatin. This method uses a mixture of chloral 
hydrate, aniline (or its hydrochloride salt), hydroxylamine 
and hydrochloric acid in aqueous medium saturated with 
heated sodium sulfate. This results in isonitrosoacetanilide 
sulfate, which is then isolated and treated with sulfuric 
acid, to ultimately generate isatin by cyclization.7 However, 
other processes for the synthesis of isatin are described in 
the literature.8
Isatin is still considered to be a promising agent during 
the planning of new drugs given its low production costs and 
its chemical structure. The possibility to introduce diverse 
chemical modifications to isatin enables the synthesis of 
new substances that have very interesting and unexplored 
biological activities.9
Isatin and its derivatives are widely related to their 
diverse biological activities that include antifungal,10,11 anti-
inflammatory and analgesic;12 antimicrobial;13 antiviral;14 
antiasthmatic;15 antioxidant;16 herbicide;17,18 anticancer,19 
among others.
The drug sunitinib, approved in 2006 by the FDA (Food 
and Drug Administration), highlights the potential of isatin 
structures in the development of new treatments for renal, 
gastrointestinal20 and pancreatic cancers.21
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The inhibition of protein kinases through an important 
indole-based compound mechanism underlies the 
anticancer activity of isatins. Protein kinases are responsible 
for regulating intra and extracellular pathways that control 
growth, differentiation and cell death.3 Krishnegowda et al.19 
showed that some N-alkylated isatins containing bromine 
atoms in positions 5 and 7 had cytotoxic activity against 
human melanoma (UACC903), breast (MCF-7), lung 
(A549), and colon (HT29) cancers. Singh et at.22 
synthesized 1,2,3-triazole-linked isatin conjugates and 
evaluated their anticancer activities against four human 
cancer cell lines, namely A549 (lung), PC-3 (prostate), 
THP-1 (leukemia) and Caco2 (colon). The most promising 
results were obtained for the THP-1 cells.
Although the exact mechanism of action of these 
compounds remains unclear, it has been suggested that they 
are able to inhibit glycogen synthase kinase 3 (GSK-3) in 
tumor cells and, consequently, cause tumor cells death.23,24
A surprising (though underestimated) protein, GSK-3 
is one of the kinases involved in phosphorylation and 
inactivation of glycogen synthase.25 The growing interest 
in this enzyme (whose action is constitutive and its 
substrates suffers pre-phosphorylation by kinases) has led 
to the discovery of GSK-3α and GSK-3β isoforms with 
remarkable homology at the catalytic site and N and C 
termini differences.26 At the N-terminus, GSK-3α has a 
63-residue glycine-rich insertion. At the C-terminus, the 
sequence homology of the last 80 residues drops to 34%. 
There is one additional GSK-3β isoform that contains a 
13 amino acid insertion in the kinase domain.27 A primed-
substrate, attracting substrates to GSK-3, and kinase, related 
to phosphorylation of ones, essential domains have been 
characterized and in both isoforms GSK-3α and GSK-3β 
a phosphorylation in Ser21 and Ser9 residues, respectively, 
is intrinsically needed for catalytic action.28
The GSK-3β is a 420-residue serine/threonine kinase. 
The first crystallographic structures of this enzyme were 
published in 2001 by Haar et al.29 These structures revealed 
a typical serine/threonine kinase fold with a small N-terminal 
domain (residues 25 to 134) and a larger C-terminal domain 
(residues 135 to 380). Moreover, the N-terminal portion was 
found to consist of seven antiparallel β-strands and the α-C 
helix. β-Strands two through six form an antiparallel β-barrel 
that is interrupted by the α-C helix (residues Arg96 to Met101) 
between β-strands five and six. The adenosine triphosphate 
(ATP) binding site is located at the interface of the N-terminal 
and C-terminal domains and is enclosed by the glycine-
rich loop (residues 60 to 70) and the hinge (residues 134 to 
139), comprising amino acids Ile62, Gly63, Asn64, Val70, 
Ala83, Lys85, Val110, Leu132, Asp133, Tyr134, Val135, 
Thr138, Arg141, Gln185, Leu188, Cys199 and Asp200.
The activation loop starts with the DFG (Asp–Phe–
Gly) motif (Asp200 to Gly202), finishes with the APE 
(Ala‑Pro‑Glu) motif (Ala224 to Glu226), and forms one 
border with the substrate-binding groove. The other edge 
is formed by the loop that connects β-strand five with the 
α-C helix. The final 55 residues after the kinase domain 
(residues 330 to 384) create a cluster of loops and helices 
that pack against the C-terminus portion. The Protein 
Data Bank (PDB) contains information about 61 GSK-3β 
structures, nine each of apo-GSK-3β and GSK-3β-peptide 
complexes and remainder of GSK-3β complexes with 
inhibitors in the ATP binding site.27
Human GSK-3β is a 46-47 kilodalton (kDa) protein 
presenting 433 amino acids in its structure and an activation 
loop portion that is pivotal for kinase activity due to the 
presence of phosphorylated residues. Ser9 and Tyr28 
phosphorylation is a precondition for enzymatic action 
regulation since these residues control the gate of the 
substrate-binding site.30,31 Ser9 is an auto-inhibition site 
that inhibits the catalytic activity when phosphorylated. 
This phosphorylation site is disordered in GSK-3β 
crystals and not identified in crystallographic information. 
Tyr216 is the phosphorylation site in the activation 
loop. Phosphorylation of Tyr216 increases the catalytic 
activity of GSK-3β. Threonine is absent in the loop of the 
primed-substrate domain in GSK-3β, and recognition of 
the primed phosphorylation on substrates occurs at this 
site. Furthermore, due to absence of a threonine residue, 
following phosphorylation of the serine residue, Ser9, the 
GSK-3β N-terminal region binds to and blocks the catalytic 
site.29,32 Finally, there is an important similarity between 
enzyme and apoenzyme structures, and the GSK-3β 
protein crystallographic structure presented as a dimer with 
identical subunits.
In this work, we describe the synthesis of 11 isatin 
derivatives that were obtained in low to high yields. 
These compounds were characterized by means of 
nuclear magnetic resonance spectrometry (NMR), 
infrared spectroscopy (IR), and high-resolution mass 
spectrometry (HRMS). Additionally, characterization of 
the isatin derivatives was performed through enzymatic 
inhibition assays and docking simulations to obtain a 
better understanding of GSK-3β structural features and 
its interactions with staurosporine.
Experimental
General experimental procedures
Analytical grade solvents with purity higher than 99.5% 
were purchased from Synth (São Paulo, Brazil). Isatin, 
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dimethylformamide (DMF), acetone azides, bromides, 
potassium carbonate, sodium ascorbate, copper sulfate, 
propargyl bromide solution (80 wt.% in toluene, containing 
0.3% of magnesium as stabilizer) and deuterated solvents 
were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Microwave reactions were conducted using a CEM 
Discover Synthesis Unit (CEM Corp., Matthews, USA). 
The instrument consists of a continuous focused microwave 
power delivery system with operator-selectable power 
output from 0 to 300 W. Reactions were performed in glass 
vessels (capacity 10 mL) sealed with a septum. Column 
chromatography (CC) was carried out using silica gel 60 
(70-230 mesh, Merck (Darmstadt, Germany)) and silica 
gel 60 ACC (6-35 µm, Chromagel-SDS, Torrance, USA) 
as the stationary phase, and mixtures of hexane and ethyl 
acetate as the mobile phase. For thin layer chromatography 
(TLC), silica gel F254 was used as the stationary phase 
with plates of dimension 20 cm × 20 cm × 0.20 mm. NMR 
(nuclear magnetic resonance) spectra were obtained with 
a Varian 400 MHz instrument (Palo Alto, USA) using 
deuterated chloroform (CDCl3) or deuterated dimethyl 
sulfoxide (DMSO-d6) as solvent and tetramethylsilane 
(TMS) as the internal standard. The chemical shift (d) is 
in ppm and J values in hertz (Hz). High resolution mass 
spectra were obtained with a Bruker Daltonics micrOTOF 
QII/ESI-TOF (Billerica, USA) by direct injection of 
the compound dissolved in methanol. This provided 
unambiguous molecular formula assignment for singly 
charged molecular ions, such as [M + H]+ or [M − H]− and 
DBE (double bound equivalents) values. The infrared (IR) 
spectrum was recorded on a Bruker Tensor 27 FT-IR 
Spectrometer (Bremen, Germany), equipped with a Pike 
MIRacle attenuated total reflection (ATR) assembly with 
a ZnSe crystal, scanning from 4000 to 600 cm-1.
Synthesis procedures
Synthesis of the compounds 2a-2f
Isatin (1) (0.05 g, 0.35 mmol) and potassium carbonate 
(0.05 g, 0.35 mmol) were added to a 50 mL round-bottom 
flask containing 4 mL of dimethylformamide (acetone in 
preparation of compound 2c). The reaction solution was 
stirred at 0 °C for 20 min. After this process, each bromide 
(a-e) (0.51 mmol) was added separately to the reaction 
solution and the mixture was stirred at room temperature 
for 3 h, leading to compounds 2a-e (Scheme 1).
The reaction solution was concentrated under reduced 
pressure. The compounds 2a-c,e were purified by column 
chromatography using silica gel 60 (70-230) mesh as the 
stationary phase and hexane:ethyl acetate 7:3 as the mobile 
phase. To purify compound 2d, an extraction with ethyl 
acetate was used.
The obtained percentages and quantitative yields of 
the compounds 2a-e were 70.29% (0.087 g, 0.23 mmol), 
29.35% (0.027 g, 0.09 mmol), 10.40% (0.013 g, 0.03 mmol) 
and 55.13% (0.048 g, 0.18 mmol), respectively.
To synthesize the compound 2f, isatin (1) (1 g, 
6.7 mmol) and potassium carbonate (0.92 g, 6.7 mmol) 
were added to a 100 mL round-bottom flask containing 
20 mL of dimethylformamide. The reaction solution 
was stirred in ice bath for 20 min. After this process, 
propargyl bromide (f) (8.37 mmol) was slowly poured 
into the reaction solution, and the solution was stirred at 
room temperature for 3 h. Afterwards, the reaction was 
concentrated under reduced pressure, resuspended in ethyl 
acetate and partitioned with water 3 times. The organic 
phase was concentrated under reduced pressure leading 
to compound 2f (Scheme 1).
Scheme 1. (i) Potassium carbonate, dimethylformamide or acetone; (ii) commercial bromide, r.t.
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Synthesis of the compounds k-l
NaN3 (1.5 equiv.) dissolved in water was slowly added 
to a 100 mL round-bottom flask containing bromide (e, 
g) (1 equiv.) in 10 mL of acetone at 0 °C. The reaction 
solution was stirred at room temperature for 3 h. After 
this process, acetone was removed under vacuum and the 
organic material was extracted with ethyl acetate that was 
further evaporated under reduced pressure generating the 
compounds k and l (Scheme 2). Their chemical structures 
were determined by IR and HRMS.
Synthesis of the compounds 4h-4l
In a 10 mL glass tube, the compound 2f (0.1 g, 
0.5 mmol), the obtained or the commercial azides 
(2.1 mmol), sodium ascorbate (0.05 mmol), 150 µL of 
a 0.1 M solution of copper sulfate, 2 mL of DMF, and a 
magnetic stir bar were combined. The vessel was sealed 
with a septum and placed into the microwave cavity. 
Microwave irradiation of 150 W was used; the temperature 
was ramped from room temperature to 70 °C, and the 
reaction mixture was held at the final temperature for 
15 min. A minor modification was made to this procedure 
for compound 4l, where the reaction mixture was held at 
70 °C for only 5 min (Scheme 3). After this process, the 
DMF was removed under vacuum.
All compounds were purified by column chromatography 
using silica gel 60 ACC (6-35 µm) as the stationary 
phase and hexane:ethyl acetate 9:1 (for compound 4j), 
hexane:ethyl acetate 7:3 (for compounds 4h, 4i and 4k) 
and hexane:ethyl acetate 4:1 (for compound 4l) as the 
mobile phase.
Percentages and quantitative yields obtained for the 
compounds 4h-l were 70.38% (0.141 g, 0.37 mmol), 
17.66% (0.032 g, 0.09 mmol), 24.12% (0.050 g, 0.12 mmol), 




It was obtained as orange powder in 70.29% yield 
(0.087 g, 0.23 mmol). TLC: retention factor (Rf) = 0.42 
(hexane:ethyl acetate 7:3 v/v); IR (ATR) νmax / cm-1 2922, 
1730, 1673, 1605, 1292, 706; 1H NMR (400 MHz, CDCl3) 
d 8.26-8.33 (m, 4H), 7.79-7.84 (m, 2H), 7.76 (dd, J 8.2, 
1.9, 1H), 7.66 (dd, J 7.8, 0.8, 1H), 7.50 (td, J 7.8, 1.2, 1H), 
7.13 (td, J 7.8, 0.8, 1H), 6.76 (brd, J 7.8, 1H), 5.10 (s, 2H); 
13C NMR (100 MHz, CDCl3) d 182.7 (CO), 182.5 (CO), 
182.4 (CO), 158.3 (CO), 150.1 (C), 141.3 (C), 138.5 (CH), 
134.4 (2C), 134.3 (C), 134.0 (CH), 133.3 (2CH), 133.2 (C), 
132.7 (CH), 128.4 (CH), 127.3 (2CH), 125.8 (CH), 124.3 
Scheme 3. (i) Azide compounds, sodium ascorbate, copper sulfate, dimethylformamide, 70 °C.
Scheme 2. (i) Sodium azide, acetone, r.t.
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(CH), 117.8 (CH), 110.6 (CH), 43.8 (CH2); high-resolution 
electrospray ionisation mass spectrometry (HRESIMS) 
m/z, calcd. for C23H14NO4+ [M + H]+: 368.0917, found: 
368.0817.
Compound 2b (1-(4-nitro-benzyl)-1H-indole-2,3-dione)
It was obtained as yellow powder in 29.35% yield 
(0.027 g, 0.09 mmol). TLC: Rf = 0.39 (hexane:ethyl acetate 
7:3 v/v); IR (ATR) νmax / cm-1 2925, 1733, 1372, 759; 1H 
and 13C NMR data were compared with the literature.33-35 
HRESIMS m/z, calcd. for C15H11N2O4+ [M + H]+: 283.0713, 




It was obtained as orange powder in 10.40% yield 
(0.013 g, 0.03 mmol). TLC: Rf = 0.20 (hexane:ethyl acetate 
1:1 v/v); IR (ATR) νmax / cm-1 2922, 1778, 1717, 1614, 727; 
1H NMR (400 MHz, CDCl3) d 7.84-7.88 (m, 2H), 7.71-7.75 
(m, 2H), 7.34 (dd, J 7.4, 0.8, 1H), 7.28 (td, J 7.8, 1.2, 1H), 
7.19 (brd, J 7.8, 1H), 7.05 (td, J 7.4, 1.2, 1H), 5.71 (d, 
J 14.1, 1H), 5.56 (d, J 14.1, 1H), 3.18 (d, J 16.8, 1H), 2.96 
(d, J 16.8, 1H), 2.19 (s, 3H); 13C NMR (100 MHz, CDCl3) 
d 207.6 (CO), 175.9 (CO), 167.3 (2CO), 140.9 (C), 134.5 
(2CH), 131.6 (2C), 130.2 (CH), 129.3 (CH), 124.0 (CH), 
123.8 (2CH), 123.6 (CH), 109.7 (CH), 74.3 (C), 48.8 
(CH2), 42.5 (CH2), 31.5 (CH3); HRESIMS m/z, calcd. for 
C20H16N2NaO5+ [M + Na]+: 387.0951, found: 387.0936.
Compound 2d (1-(4-fluoro-benzyl)-1H-indole-2,3-dione)
It was obtained as orange powder in 55.13% yield 
(0.048 g, 0.18 mmol). TLC: Rf = 0.58 (hexane:ethyl 
acetate 7:3 v/v); IR (ATR) νmax / cm-1 2924, 1726, 1608, 
762; 1H NMR data were compared with the literature.36,37 
HRESIMS m/z, calcd. for C15H11FNO2+ [M + H]+: 256.0768, 
found: 256.0764; HRESIMS m/z, calcd. for C15H10FNNaO2+ 
[M + Na]+: 278.0588, found: 278.0583; HRESIMS m/z, 




It was obtained as orange powder in quantitative yield. 
TLC: Rf = 0.57 (hexane:ethyl acetate 1:1 v/v); IR (ATR) 
νmax / cm-1 3497, 1739, 1663, 1609, 1141, 721; 1H NMR 
(400 MHz, DMSO-d6) d 7.85-7.89 (m, 2H), 7.78 (tt, J 7.4, 
1.2, 1H), 7.66 (td, J 7.4, 1.6, 2H), 7.60 (dd, J 7.4, 1.2, 1H), 
7.56 (td, J 7.8, 1.2, 1H), 7.40 (dd, J 7.8, 1.2, 1H), 7.27 (td, 
J 7.4, 1.2, 1H), 7.22 (td, J 7.4, 1.2, 1H), 7.10-7.16 (m, 2H), 
6.80 (d, J 8.2, 1H), 5.07 (s, 2H), 4.91 (s, 2H); 13C NMR 
(100 MHz, DMSO-d6) d 183.0 (CO), 158.6 (CO), 150.2 
(C), 138.8 (C), 137.8 (CH), 135.3 (C), 134.1 (CH), 133.4 
(CH), 129.4 (2CH), 129.0 (CH), 128.1 (2CH), 127.3 (CH), 
127.1 (CH), 126.3 (C), 124.4 (CH), 123.4 (CH), 118.0 (C), 
111.2 (CH), 57.9 (CH2), 41.1 (CH2); HRESIMS m/z, calcd. 
for C22H17NNaO4S+ [M + Na]+: 414.0770, found: 414.0768; 
HRESIMS m/z, calcd. for C22H17KNO4S+ [M + K]+: 
430.0510, found: 430.0509; HRESIMS m/z, calcd. for 
C44H34N2NaO8S2+ [2M + Na]+: 805.1649, found: 805.1640.
Compound 2f (1-prop-2-ynyl-1H-indole-2,3-dione)
It was obtained as orange powder in quantitative 
yield. TLC: Rf = 0.75 (hexane:ethyl acetate 1:1 v/v); IR 
(ATR) νmax / cm-1 3263, 2360, 1735, 1614, 1343, 677; 1H 
and 13C NMR data were compared with the literature.38,39 
HRESIMS m/z, calcd. for C11H7NNaO2+ [M + Na]+: 
208.0369, found: 208.0369; HRESIMS m/z, calcd. for 
C22H14N2NaO4+ [2M + Na]+: 393.0846, found: 393.0848.
Compound 4h (1-[1-(4-trifluoromethyl-phenyl)-1H-[1,2,3]
triazol-4-ylmethyl]-1H-indole-2,3-dione)
It was obtained as orange powder in 70.38% yield 
(0.141 g, 0.37 mmol). TLC: Rf = 0.67 (hexane:ethyl acetate 
1:1 v/v); IR (ATR) νmax / cm-1 3145, 1739, 1721, 1612, 1154, 
751; 1H NMR (400 MHz, DMSO-d6) d 8.98 (s, 1H), 8.10 
(d, J 8.6, 2H), 7.96 (d, J 8.6, 2H), 7.64 (brt, J 7.8, 1H), 7.59 
(brd, J 7.4, 1H), 7.20 (brd, J 8.2, 1H), 7.15 (brt, J 7.8, 1H), 
5.08 (s, 2H); 13C NMR (100 MHz, DMSO-d6) d 183.1 (CO), 
158.0 (CO), 150.1 (C), 143.3 (C), 139.3 (C), 138.2 (CH), 
127.3 (C), 127.3 (2CH), 125.2 (2CH), 124.6 (CH), 123.2 
(CH), 122.1 (CH), 120.6 (C), 117.8 (C), 111.2 (C), 35.0 
(CH2); HRESIMS m/z, calcd. for C18H12F3N4O2+ [M + H]+: 
373.0907, found: 373.0907; HRESIMS m/z, calcd. for 
C18H11F3N4NaO2+ [M + Na]+: 395.0726, found: 395.0720; 
HRESIMS m/z, calcd. for C18H11F3KN4O2+ [M + K]+: 
411.0466, found: 411.0486; HRESIMS m/z, calcd. for 
C36H22F6N8NaO4+ [2M + Na]+: 767.1560, found: 767.1529.
Compound 4i (1-[1-(2-methoxy-phenyl)-1H-[1,2,3]triazol-
4-ylmethyl]-1H-indole-2,3-dione)
It was obtained as orange powder in 16.66% yield 
(0.032 g, 0.09 mmol). TLC: Rf = 0.48 (hexane:ethyl 
acetate 1:1 v/v); IR (ATR) νmax / cm-1 2925, 1741, 1613, 
1005, 752; 1H NMR (400 MHz, DMSO-d6) d 8.51 (s, 1H), 
7.65 (brt, J 7.8, 1H), 7.57 (brd, J 7.4, 2H), 7.51 (brt, J 8.2, 
1H), 7.29 (brd, J 8.2, 1H), 7.23 (d, J 7.8, 1H), 7.09-7.16 
(m, 2H), 5.06 (s, 2H), 3.81 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6) d 183.1 (CO), 157.9 (CO), 151.6 (C), 150.2 
(C), 141.3 (C), 138.1 (CH), 130.8 (C), 125.7 (2CH), 
125.6 (CH), 124.5 (CH), 123.4 (CH), 120.9 (CH), 117.7 
(C), 113.1 (CH), 111.3 (CH), 56.2 (CH3), 35.0 (CH2); 
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HRESIMS m/z, calcd. for C18H15N4O3+ [M + H]+: 335.1139, 
found: 335.1140; HRESIMS m/z, calcd. for C18H14N4NaO3+ 
[M + Na]+: 357.0958, found: 357.0977.
Compound 4j (1-[1-(4-bromo-phenyl)-1H-[1,2,3]triazol-
4-ylmethyl]-1H-indole-2,3-dione)
It was obtained as orange gel in 24.12% yield (0.050 g, 
0.12 mmol). TLC: Rf = 0.61 (hexane:ethyl acetate 1:1 v/v); 
IR (ATR) νmax / cm-1 2917, 1735, 1718, 1496, 749; 1H NMR 
(400 MHz, DMSO-d6) d 8.88 (s, 1H), 7.82 (d, J 9.0, 2H), 
7.78 (d, J 9.0, 2H), 7.64 (td, J 7.8, 1.2, 1H), 7.59 (brd, 
J 7.4, 1H), 7.19 (brd, J 7.8, 1H), 7.14 (t, J 7.4, 1H), 5.06 (s, 
2H); 13C NMR (100 MHz, DMSO-d6) d 183.1 (CO), 158.0 
(CO), 150.1 (C), 143.0 (C), 138.2 (CH), 135.7 (C), 132.8 
(C), 124.5 (CH), 123.5 (CH), 121.9 (3CH), 121.4 (2CH), 
117.7 (C), 111.1 (CH), 35.0 (CH2); HRESIMS m/z, calcd. 
for C17H12BrN4O2+ [M + H]+: 383.0138, found: 383.0139.
Compound 4k (1-[1-(2-benzenesulfonylmethyl-benzyl)-
1H-[1,2,3]triazol-4-ylmethyl]-1H-indole-2,3-dione)
It was obtained as orange powder in 19.43% yield 
(0.012 g, 0.02 mmol). TLC: Rf = 0.51 (hexane:ethyl acetate 
1:1 v/v); IR (ATR) νmax / cm-1 2924, 1734, 1610, 1262, 755; 
1H NMR (400 MHz, DMSO-d6) d 8.14 (s, 1H), 7.80 (m, 
2H), 7.75 (dt, J 8.2, 1.2, 1H), 7.66 (m, 2H), 7.60 (dd, J 7.8, 
1.2, 1H), 7.55 (dd, J 7.4, 1.2, 1H), 7.30 (td, J 7.4, 1.5, 1H), 
7.24 (td, J 7.4, 1.5, 1H), 7.08-7.14 (m, 3H), 7.00 (dd, J 7.8, 
0.8, 1H), 5.63 (s, 2H), 4.95 (s, 2H), 4.87 (s, 2H); 13C NMR 
(100 MHz, DMSO-d6) d 183.1 (CO), 157.9 (CO), 150.2 
(C), 142.0 (C), 138.5 (C), 138.1 (CH), 136.4 (C), 134.2 
(CH), 133.2 (CH), 129.4 (2CH), 129.3 (CH), 128.7 (CH), 
128.2 (CH), 128.1 (2CH), 126.6 (C), 124.5 (CH), 124.1 
(CH), 123.5 (CH), 117.7 (C), 111.2 (CH), 57.8 (CH2), 50.2 
(CH2), 35.1 (CH2); HRESIMS m/z, calcd. for C25H21N4O4S+ 
[M + H]+: 473.1278, found: 473.1275; HRESIMS m/z, 
calcd. for C25H20N4NaO4S+ [M + Na]+: 495.1097, found: 
495.1092; HRESIMS m/z, calcd. for C25H20KN4O4S+ 
[M + K]+: 511.0837, found: 511.0843.
Compound 4l  (4-[4-(2,3-dioxo-2,3-dihydro-indol-
1-ylmethyl)-[1,2,3]triazol-1-ylmethyl]-benzoic acid)
It was obtained as orange powder in 51.44% yield 
(0.030 g, 0.08 mmol). TLC: Rf = 0.27 (hexane:ethyl acetate 
1:1 v/v); IR (ATR) νmax / cm-1 3368, 2925, 1713, 1610, 1608, 
1380, 747; 1H NMR (400 MHz, DMSO-d6) d 8.20 (s, 1H), 
7.84 (d, J 8.2, 2H), 7.62 (td, J 7.8, 1.2, 1H), 7.55 (brd, J 7.4, 
1H), 7.16 (d, J 8.2, 2H), 7.12 (m, 2H), 5.55 (s, 2H), 4.95 
(s, 2H); 13C NMR (100 MHz, DMSO-d6) d 183.1 (CO), 
169.5 (COOH), 157.8 (CO), 150.2 (C), 141.7 (C), 139.5 
(C), 138.1 (CH), 136.5 (C), 129.4 (2CH), 126.8 (2CH), 
124.5 (CH), 123.8 (CH), 123.4 (CH), 117.6 (C), 111.2 
(CH), 52.8 (CH2), 35.1 (CH2). HRESIMS m/z, calcd. for 
C19H13N4O4– [M − H]−: 361.0942, found: 361.0941.
Molecular docking
Docking assays were performed using the program Gold 
Suite 5.1 (Genetic Optimization for Ligand Docking 5.1) 
(CCDC Software Limited).40 A genetic algorithm of the 
crystallographic structure of GSK-3β from Homo sapiens 
(code protein data bank (PDB): 1Q3D), at 2.2 Å resolution, 
was used. The binding mode of the compounds 2b and 2e 
was predicted. The predicted binding modes showed that 
both isatin derivatives exhibit similar complementarity 
(similar to staurosporine, with a score value 65.95), to the 
ATP-binding site of GSK-3β (PDB code 1Q3D). GOLD 
was used by a GoldScore fitness function, a molecular 
mechanism for the calculation of binding positions of 
ligand. Docking simulations were performed inside a 10 Å 
radius sphere centered at the ligand in chain A, and using 
the pattern parameters available, namely a population of 
100 conformers, 100,000 operations, 95 mutations and 
95 crossovers. The docked lowest-energy structure has a 
root mean square deviation (RMSD) of 0.75 Å from the 
corresponding crystallographic complex.
Biological assays
The N-alkyl isatin derivatives (2a-e and 4h-l) were 
evaluated for their potential inhibitory effect against the 
GSK-3β enzyme. All compounds were diluted in dimethyl 
sulfoxide (DMSO). In all experiments, 0.2 µg µL-1 of 
GSK-3β substrate, 25 µM of ATP and 1 ng of GSK-3β 
enzyme were incubated together with the compounds under 
study for 60 min. A commercial kit of luminescent kinase 
assay was used according to the supplier’s instructions 
(Promega, V9371, Brazil). For the calculation of the half 
maximal inhibitory concentration (IC50), a two-fold dilution 
was performed across each 96-well plate, starting with the 
highest isatin concentration (25, 50 or 100 µM depending 
on the isatin solubility and availability) up to 0.1 µM. For 
each test compound, a dose-response curve was generated. 
Results were represented as log (concentration of inhibitor) 
vs. response (Figure S71, Supplementary Information 
(SI) section), and, using the GraphPad program41 and a 
non-linear fit of the data, the IC50 value were determined.
Results and Discussion
In this work, comercial isatin was used as a starting 
material for bimolecular nucleophilic substitution and a 
click chemistry approach to develop all described chemical 
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reactions. These reactions provide 11 semisynthetic isatin 
derivatives, seven of which are new. Despite their simple 
chemical structures, their biological activities were found 
to be notable. All 11 compounds were characterized using 
IR, NMR and HRMS.
The NMR data for all obtained compounds related to 
the isatin moiety were practically the same. We observed 
four signals related to aromatic hydrogens in the 1H NMR 
spectra. The coupling constant of these hydrogens is 
characteristic of a 1,2-dissubstitute aromatic ring. The 
13C NMR spectra shows two signals at approximately d 158 
and 182 ppm related to the carbons of the ketone and amide 
functions of isatin.
The HRESIMS of 2a were performed in a positive 
mode and showed the molecular ion peak at m/z 368.0817 
in accordance with the molecular formula C23H13NO4. In 
the IR spectra, two stretching vibration bands of the C=O 
bonds were observed at 1673 and 1605 cm-1, related to 
the carbonyl groups of the anthraquinone moiety. Aside 
from the characteristic isatin signals, the 1H and 13C NMR 
spectra of 2a showed signals at d 5.10 ppm (s, 2H) and 
d 43.8 ppm, respectively, related to the methylene group 
attached to pyrrole-2,3-dione ring. This signal shows the 
coupling between isatin and the anthraquinone moiety. 
Additional aromatic signals were observed in the range 
d 7.76 to 8.31 ppm and were attributed to the anthraquinone 
ring. In the 13C NMR spectrum, two signals were observed 
at d 182.5 and 182.7 ppm attributed to the carbonyl groups 
of the anthraquinone rings. Additional signals from the 
aromatic carbons of the anthraquinone ring were observed 
in the range of d 127.3-141.3 ppm.
Compounds 2b and 2d are known, and the structures 
were confirmed by comparing the data obtained to results 
reported in the literature.33-37
For 2e, the data obtained with HRESIMS established 
the molecular formula to be C22H17NO4S. The IR spectrum 
shows a characteristic absorption band at 1141 cm-1 
related to the sulfone group stretch. In the 1H NMR 
spectrum signals at d 5.07 ppm (s, 2H), related to the 
methylene group attached to pyrrole-2,3-dione ring, and 
d 4.91 ppm (s, 2H), related to the other methylene group, 
were observed. Four aromatic hydrogens signals in the 
range d 7.10-7.40 ppm were observed, which, together 
with the observed coupling constant, allowed us to 
determine the presence of a 1,2-dissubstitute aromatic 
ring in the structure. Additionally, signals in the range 
of d 7.66-7.85 ppm associated with aromatic hydrogens 
of other aryl groups, along with the observed coupling 
constant, permitted us to determine the presence of a 
monosubstituted ring in the structure, confirming the final 
structure of 2e. Despite the isatin signals, signals in the 
13C NMR spectrum related to two additional aryl groups 
were observed in addition to signals from two methylene 
carbons at d 41.1 and 57.9 ppm.
The compound 2f was prepared as a starting material to 
produce the triazole derivatives by click chemistry reactions 
with organic azides. Compound 2f is known and its NMR 
data were compared with data reported in the literature.38,39
As for compounds 2a-f, signals related to isatin were 
also observed for the compounds 4h-l and will not be 
discussed.
The molecular formulae of compounds 4h-l were 
obtained by HRESIMS. The 1H NMR spectra of 4h-l 
showed a hydrogen singlet in the range d 8.14-8.98 ppm 
correlated to the hydrogen of the triazole ring. Signals 
related to the methylene group attached to pyrrole-2,3-dione 
ring were observed in the range d 4.95-5.08 ppm. The 13C 
spectra of these compounds showed signals in the range 
d 122.1-125.7 ppm and 141.3-143.3 ppm related to the 
triazole ring carbons.
The IR spectrum of 4h shows an absorption band at 
1154 cm-1 related to the C−F stretch. The 1H NMR spectrum 
of 4h showed two signals at d 7.96 ppm (d, J 8.6, 2H) and 
8.10 ppm (d, J 8.6, 2H) attributed to a 1,4-dissubstitute 
aromatic ring. The 13C NMR spectrum showed a signal 
from the aryl group attached to the triazole ring in the range 
d 125.2-139.3 ppm, and a signal at d 120.6 ppm attributed 
to a CF3 carbon.
The IR spectrum of 4i shows an absorption band at 
1005 cm-1 related to the stretch of alkyl-aryl-ether. The 
1H NMR spectrum of 4i showed signals of aromatic 
hydrogens in the range d 7.09-7.57 ppm. The coupling 
constant analysis of these hydrogens suggested the presence 
of a 1,2-dissubstitute aromatic ring in the structure. An 
additional signal was observed at d 3.81 ppm indicating the 
presence of a methoxy group. In the 13C NMR spectrum, 
signals were observed at d 151.6 ppm, associated with a 
phenolic group, at d 56.2 ppm related to a methoxy carbon, 
and in the range d 120.9-130.8 ppm due to aryl carbons.
Compound 4j is known in the literature,42 however, 
its NMR data have not been discussed in the previously 
published work. The IR spectrum of 4j shows a characteristic 
absorption band at 1496 cm-1 related to the C−Br stretch. 
The 1H NMR spectrum of 4j showed two signals at 
d 7.78 ppm (d, J 9.0, 2H) and 7.82 ppm (d, J 9.0, 2H) 
attributed to a 1,4-dissubstitute aromatic ring. The 13C NMR 
spectrum showed signal of the aryl group attached to the 
triazole ring in the range d 121.4-135.7 ppm related to a 
bromobenzene ring.
For 4k, the IR spectrum showed a characteristic 
absorption band at 1262 cm-1 related to the stretch of a 
sulfone group. In the 1H NMR spectrum, an additional 
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methylene group signal at d 4.87 ppm (s, 2H) was observed 
and was attributed to a methylene sulfone group. Four 
aromatic hydrogens signals in the range d 7.00-7.30 ppm 
were observed, which, together with the coupling constant, 
allowed us to determine the presence of a 1,2-dissubstitute 
aromatic ring in the structure. Additionally, signals from 
aromatic hydrogens of other aryl groups in the range 
d 7.66-7.80 ppm were observed; coupling constant analysis 
allowed us to determine the presence a monosubstituted 
ring in the structure. Despite of the isatin signals, signals 
in the 13C NMR spectrum related to two additional aryl 
groups in the range d 126.6-138.5 ppm were observed in 
addition to two methylene carbons at d 50.2 and 57.8 ppm.
The IR spectrum of 4l shows characteristic absorption 
bands at 3368, 1713 and 1380 cm-1 related to the stretch of 
O−H, C=O and C−O, respectively. The 1H NMR spectrum 
of 4l showed two signals at d 7.16 ppm (d, J 8.2, 2H) and 
7.84 ppm (d, J 8.2, 2H) attributed to a 1,4-dissubstitute 
aromatic ring. An additional methylene group at d 5.58 ppm 
(s, 2H) was observed. The 13C NMR spectrum showed a 
signal of the aryl group in the range d 126.8-139.5 ppm, 
and a signal at d 169.5 ppm confirms the presence of a 
COOH group.
During the preparation of the N-alkyl isatin derivatives, 
interesting and unexpected events occurred regarding 2c. 
Synthesis and biological properties of N-alkyl isatin 
derivatives are broadly described in the literature.16,43,44 
These methods are simple and easy, and they differ from 
each other in the bases and solvents used. However, in 
our study, in addition to using bimolecular nucleophilic 
substitution to synthesize a convenient isatin derivative, 
we used potassium carbonate and N-(bromomethyl)
phthalimide to prepare a novel isatin derivative named 2c 
that resulted from a nucleophilic addition in the carbonyl 
group at position 3 of isatin. The proposed mechanism 
towards the synthesis of 2c is illustrated in Figure 1. 
Synthesis occurs via the enolate anion that is obtained from 
the reaction between potassium carbonate and acetone, 
which participates as both solvent and reagent. Thus, the 
nucleophile enolate anion attacks the carbonyl group at 
C-3 and consequently leads to the production of alcoxide 
anion and, finally, alcohol in 2c.
The HRESIMS of 2c was performed in the positive 
mode. The ion peak at m/z 387.0936 is consistent with the 
molecular formula C20H16N2O5. The two signals observed 
in the 1H NMR spectrum at d 7.71-7.75 ppm (m, 2H) and 
7.84-7.88 ppm (m, 2H), and from the coupling constant we 
determined the presence of a 1,2-dissusbstitute symmetric 
aromatic ring. Th signal observed in the 13C NMR spectrum 
at d 167.3 ppm confirmed the presence of the amide group 
in the phthalimide moiety. Two hydrogens at d 5.71 ppm 
(d, J 14.1, 1H) and 5.56 ppm (d, J 14.1, 1H) confirmed the 
presence of a methylene group.
Nucleophilic addition to the carbonyl group at position 3 
was confirmed by the signal at d 73.3 ppm that demonstrated 
the reduction of the ketone group. Two hydrogens at 
2.96 ppm (d, J 16.8, 1H) and 3.18 ppm (d, J 16.8, 1H) confirm 
the presence of other methylene groups in the structure. To 
finish, the carbon signals at d 207.6 and 31.5 ppm show the 
nucleophilic addition of the enolate anion.
Figure 1. Proposed mechanism towards the synthesis of 2c.
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Docking studies on isatin derivatives
Staurosporine is  an alkaloid containing an 
indolo[2,3-a]carbazolole nucleus which has remarkable 
inhibitory activity against GSK-3β protein kinase, with 
an IC50 of 15 nM. This alkaloid was first obtained from 
Streptomyces staurosporeus, and its crystallographic 
structure in a complex with GSK-3β (PDB code 1Q3D) 
highlights important interactions related to enzymatic 
inhibition. Regarding the ATP-binding site in GSK-3β, 
direct hydrogen bond interactions are disclosed involving 
N1 of staurosporine with the Asp133 carbonyl oxygen, 
and the O5 of staurosporine with the backbone nitrogen 
of Val135. A water-mediated hydrogen bond is also 
observed between the carbonyl group in Gln185 and N 
at position 4 in the glycosidic portion.45 Furthermore, a 
hydrogen-bonding network can be seen, consisting of 
the Thr138 residue, 4 water molecules as intermediates 
and finally the carbonyl group in Val135 (Figure 2). The 
fused carbazole portion in this alkaloid, which interacts 
with water molecules to form a cavity, has interesting 
hydrophobic interactions at the GSK-3β ATP-binding 
site. Ile62, Gly63, Gly65, Val70, Ala83, Asp133, Tyr134, 
Gln185, Asn186, Leu188, Cys199 and Asp200 are 
residues involved in hydrophobic interactions and are part 
of the buried surface area in the staurosporine-GSK-3β 
crystallographic structure.46
To gain a better understanding of the inhibitory activity 
of 2b, we analysed its interactions with GSK-3β. All docking 
runs applied the genetic algorithm of GOLD 5.1. The 
binding mode of compound 2b (the most active compound 
assayed) onto the GSK-3β ATP-binding site is depicted in 
Figure 3. All amino acid residues that had interactions with 
this isatin derivative are exhibited. In the binding mode, 
2b (score value 43.33) is nicely complexed with GSK-3β 
and stabilized by two remarkable hydrogen bonds with 
important aminoacids at the catalytic site. Furthermore, 
a superposition of 2b and staurosporine reveals that both 
compounds are located at the edge of the ATP binding-site, 
suggesting that 2b acts as an ATP-mimetic inhibitor. The 
oxygen atom of the nitro group in 2b formed a hydrogen 
bond with the −NH2 moiety in the Asp200 residue (3.3 Å), 
similar to the inhibitor indirubin-3’-monoxime.46 Another 
notable hydrogen bond is formed by the oxygen atom of 
the carbonyl group of 2b and the −NH2 group present in the 
side chain of Gly65 (3.0 Å). This interaction is important 
since this residue contributes to the stabilization and surface 
area in the GSK-3β active site.
Figure 2. (a) Binding of staurosporine (blue) to GSK-3β with ASP133 and VAL135 aminoacids directly related to an inhibitory role; (b) crystallographic 
information of GSK-3β and its relevant groups.
Figure 3. (a) Overview of the 3D structure of GSK-3β highlighting the region for catalysis or inhibitor binding. The structure of 2b (light blue, carbon) is 
close to the staurosporine structure (yellow, carbon) showing complementarity with the ATP binding site; (b) detailed view of 2b and nearby residues in the 
active site, with dashed lines showing hydrogen bonds and distances. All interactions shown are less than 4.5 Å and therefore are capable of hydrogen bonding.
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With respect to the binding mode of the isatin 
derivative 2e, which presented the best score value of 
66.34, interactions with staurosporine highlight that 2e is 
capable of forming hydrogens bonds with the GSK-3β ATP 
binding site (Figure 4). In the binding mode prediction, 
complementarity of 2e to the ATP binding site on GSK-3β 
is observed, like 2b (as discussed above). Stabilization 
is achieved by two strong hydrogen bonds, between the 
amino terminal moiety in Lys85 and (i) the oxygen atom in 
carbonyl at position 2 in isatin (2.4 Å), and (ii) the sulfonyl 
group (2.7, 3.0 Å). Moreover, a water-mediated hydrogen 
bond, W580, permits an interaction between carbonyl, at 
position 2 in this derivative, and the –NH2 moiety of the 
Asp200 residue.
The docking results confirmed that the aforementioned 
hydrogen bonding interactions might contribute to the 
powerful biological activities found for 2b and 2e N-alkyl 
isatin derivatives. Moreover, these results contribute to a 
better understanding of important pharmacophoric features 
required to further develop isatin derivatives holding anti-
GSK-3β activity, namely contain voluminous groups, as 
seen in 2e structure, and/or electronegative groups, as seen 
in 2b structure. Table 1 summarizes the score value and 
interactions for chemical groups found to be interesting 
for inhibitory activity.
Inhibitory effect of isatin derivatives on GSK-3β enzyme
The isatin derivative’s ability to inhibit the GSK-3β 
enzyme was evaluated in vitro. The concentrations of 
inhibitor required to reach 50% enzymatic inhibition under 
the given experimental conditions (IC50) are summarized 
in Table 2. As previously mentioned, staurosporine is 
described in the literature as a pattern inhibitor of GSK-3β 
with an IC50 value of 15 nM.47 A wide range of IC50 values 
were obtained for the different isatin derivatives tested and 
are related to the substituents at N-1 in the isatin building 
block.
A strong inhibitory activity against the GSK-3β enzyme 
was identified for all isatin derivatives studied, with 2b 
and 4h derivatives being the most effective. Stronger 
inhibitory ability was correlated with the addition of 
bulkier and/or electronegative substituents. Comparing 





Key amino acids to hydrogen bond interactions 
in ATP-binding site
2a 58.06
−NH2 Lys85: C=O (C2) 2.9 Å,  
−NH2 Lys85: C=O (anthraquinone) 2.8 Å
2c 52.07
−NH2 Lys85: C=O (phthalimide) 2.6 Å,  
−NH2 Lys183: −OH 3.2 Å
2d 42.67 −NH2 Lys85: C=O (C2) 2.5 Å
4h 50.88 −NH2 Lys85: C=O (C2) 2.5 Å
4i 55.02 −NH Gly65: C=O (C3) 3.1 Å
4j 52.59 −NH2 Lys85: C=O (C2) 2.4 Å
4k 65.43
−OH Ser66: C=O (C3) 3.4 Å,  
−NH Phe67: C=O (C2) 3.5 Å
4l 58.83
−NH Asp200: C=O(COOH) 3.4 Å,  
−NH2 Lys85: C=O (C3) 2.5 Å
Table 2. Inhibition effect of isatin derivatives against the GSK-3β enzyme
Compound IC50 value / µM
2a 1.363
2b 4.612 × 10-1
2c 1.531 × 102
2d 4.106 × 101
2e 5.397
4h 7.320 × 10-1




IC50: half maximal inhibitory concentration.
Figure 4. (a) Overview of the 3D structure of GSK-3β. The structure of 2e (light blue, carbon) is close to the staurosporine structure (yellow, carbon) showing 
complementarity to the ATP-binding site; (b) detailed view of 2e and nearby residues in the active site. Dashed lines showing hydrogen bonds and distances.
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the isatin derivatives 2b and 2d, both contain a para-
substituted benzene ring. However, 2b, which has a nitro 
group as a substituent with greater electron-withdrawing 
effect, exhibited significantly better inhibitory ability 
(IC50 = 4.612 × 10-1 µM) than 2d, which has a fluorine 
group. Thus, the presence of more electronegative groups 
as substituents appears to be important. Compared with 2a 
and 2e which contain a less bulky groups, 2b has superior 
inhibitory ability. Regarding the triazolic isatin derivatives 
shown in Scheme 3, a similar correlation was given to 
the substituents of the benzyl ring. The isatin derivatives 
4h, 4j and 4l showed IC50 values significantly better than 
4i (IC50 = 1.926 × 101 µM), which has an electron-donor 
effect related to the –OCH3 group. Furthermore, of these 
para-substituted compounds, 4h has a better IC50 value 
(0.7323 µM), probably owing to the greater electron-
withdrawing ability of the –CF3 group. Both 2e and 4k 
derivatives possess a 2-benzenesulfonylmethyl-benzyl as 
a substituent; however, it was found that the 4k, spaced 
by a triazol ring, has an IC50 value, 3.442 µM, performing 
better than to 2e, with an IC50 of 5.397 µM. These results 
are in accordance with the observation that bulkier groups 
are associated with greater inhibitory potential, further 
suggesting that the triazolic ring plays an important role. 
Finally, from analysis of the results for the 2c derivative, 
preserving the carbonyl portions of the isatin scaffold was 
found to be crucial; this derivative had the worst IC50 value, 
most likely because of the nucleophilic addition that occurs 
during its preparation.
Conclusions
Of all tested compounds, the N-alkyl isatin 2b and 4h 
derivatives, with IC50 values of 0.4612 and 0.7323 µM, 
respectively, were found to be the most effective against 
GSK-3β enzyme. This better activity was attributed to the 
presence of a group with greater electron-withdrawing 
ability in a para-position. Moreover, the existence of 
bulkier substituents was also found to be crucial to improve 
the inhibitory activity against GSK-3β, as seen for 2a, 2e 
and 4k. Moreover, the binding mode prediction of 2b and 
2e through docking studies provided better insight into 
the hydrogen bond interactions with the GSK-3β ATP-
binding site.
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